BioCardia Files 8-K: Regulation FD & Financials
Ticker: BCDA · Form: 8-K · Filed: Aug 30, 2024 · CIK: 925741
| Field | Detail |
|---|---|
| Company | Biocardia, Inc. (BCDA) |
| Form Type | 8-K |
| Filed Date | Aug 30, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 B |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, financials, regulation-fd
TL;DR
BioCardia dropped an 8-K on Aug 30th covering Reg FD and financials. Check it out.
AI Summary
BioCardia, Inc. filed an 8-K on August 30, 2024, reporting under Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Tiger X Medical, Inc., is incorporated in Delaware and headquartered in Sunnyvale, California.
Why It Matters
This filing provides important updates on BioCardia's regulatory disclosures and financial reporting, which are crucial for investors to assess the company's current status.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, primarily for disclosure and financial reporting, without immediate significant operational or financial news.
Key Numbers
- 001-38999 — SEC File Number (Identifies the company's filing with the SEC.)
- 23-2753988 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- BioCardia, Inc. (company) — Registrant
- Tiger X Medical, Inc. (company) — Former company name
- August 30, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Sunnyvale, California (location) — Principal executive offices
FAQ
What specific information is being disclosed under Regulation FD?
The filing indicates a Regulation FD Disclosure, but the specific details of the disclosure are not provided in this header information.
What financial statements or exhibits are included with this 8-K?
The filing lists 'Financial Statements and Exhibits' as an item, but the content of these documents is not detailed in the provided text.
When was BioCardia, Inc. previously known by another name?
BioCardia, Inc. was formerly known as Tiger X Medical, Inc., with a name change date of June 16, 2011.
Where are BioCardia, Inc.'s principal executive offices located?
The principal executive offices of BioCardia, Inc. are located at 320 Soquel Way, Sunnyvale, California 94085.
What is the SIC code for BioCardia, Inc.?
The Standard Industrial Classification (SIC) code for BioCardia, Inc. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 437 words · 2 min read · ~1 pages · Grade level 10.5 · Accepted 2024-08-30 08:00:10
Key Financial Figures
- $0.001 B — ch registered Common Stock, par value $0.001 BCDA The Nasdaq Capital Market Indicat
Filing Documents
- bcda20240830_8k.htm (8-K) — 26KB
- ex_719972.htm (EX-99.1) — 10KB
- 0001437749-24-028087.txt ( ) — 168KB
- bcda-20240830.xsd (EX-101.SCH) — 3KB
- bcda-20240830_def.xml (EX-101.DEF) — 11KB
- bcda-20240830_lab.xml (EX-101.LAB) — 15KB
- bcda-20240830_pre.xml (EX-101.PRE) — 11KB
- bcda20240830_8k_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On August 30, 2024, BioCardia, Inc. (the "Company") issued a press release announcing the pricing of its upsized public offering with participation from management, directors, institutional investors and certain existing investors of the Company for a purchase and sale of common stock and warrants. A copy of the press release is attached hereto as Exhibit 99.1 to this current report on Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 BioCardia, Inc. press release dated August 30, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCARDIA, INC. /s/ Peter Altman, Ph.D. Peter Altman, Ph.D. President and Chief Executive Officer Date: August 30, 2024